Market Cap
€149.3m
Last Updated
2020/01/22 21:25 UTC
Data Sources
Company Financials +
Executive Summary
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages.
Risk Analysis
Earnings are forecast to decline by an average of -10.6% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and overvalued.
Similar Companies
Share Price & News
How has Medigene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDG1's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-3.5%
MDG1
1.5%
DE Biotechs
0.5%
DE Market
1 Year Return
-32.8%
MDG1
5.8%
DE Biotechs
15.5%
DE Market
Return vs Industry: MDG1 underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: MDG1 underperformed the German Market which returned 17.1% over the past year.
Shareholder returns
| MDG1 | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.5% | 1.5% | 0.5% |
| 30 Day | 49.1% | -2.9% | 1.4% |
| 90 Day | 3.6% | 11.2% | 5.3% |
| 1 Year | -32.8%-32.8% | 6.0%5.8% | 19.2%15.5% |
| 3 Year | -53.5%-53.5% | 60.1%58.3% | 15.7%5.5% |
| 5 Year | 64.3%64.3% | 16.1%13.7% | 27.3%10.1% |
Price Volatility Vs. Market
How volatile is Medigene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Kind Of Shareholders Own Medigene AG (ETR:MDG1)?1 month ago | Simply Wall St
Does The Medigene AG (ETR:MDG1) Share Price Fall With The Market?2 months ago | Simply Wall St
Does Medigene AG's (ETR:MDG1) CEO Salary Reflect Performance?Valuation
Is Medigene undervalued compared to its fair value and its price relative to the market?
1.74x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDG1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDG1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDG1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MDG1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDG1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDG1 is good value based on its PB Ratio (1.7x) compared to the DE Biotechs industry average (3.4x).
Next Steps
Future Growth
How is Medigene forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
-15.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDG1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDG1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDG1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDG1's revenue (2.3% per year) is forecast to grow slower than the German market (4.8% per year).
High Growth Revenue: MDG1's revenue (2.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDG1's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Medigene performed over the past 5 years?
-22.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDG1 is currently unprofitable.
Growing Profit Margin: MDG1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDG1 is unprofitable, and losses have increased over the past 5 years at a rate of -22.9% per year.
Accelerating Growth: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: MDG1 has a negative Return on Equity (-27.85%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Medigene's financial position?
Financial Position Analysis
Short Term Liabilities: MDG1's short term assets (€65.6M) exceed its short term liabilities (€12.9M).
Long Term Liabilities: MDG1's short term assets (€65.6M) exceed its long term liabilities (€18.8M).
Debt to Equity History and Analysis
Debt Level: MDG1 is debt free.
Reducing Debt: MDG1 has not had any debt for past 5 years.
Balance Sheet
Inventory Level: MDG1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if MDG1's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDG1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MDG1 has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -24.1% each year.
Next Steps
Dividend
What is Medigene's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MDG1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MDG1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDG1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDG1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDG1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of Medigene's salary, the management and board of directors tenure and is there insider trading?
1.8yrs
Average management tenure
CEO
Dolores Schendel 0
3.9yrs
Tenure
€568,000
Compensation
Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief ...
CEO Compensation Analysis
Compensation vs Market: Dolores's total compensation ($USD631.88K) is about average for companies of similar size in the German market ($USD638.09K).
Compensation vs Earnings: Dolores's compensation has been consistent with company performance over the past year.
Management Age and Tenure
1.8yrs
Average Tenure
Experienced Management: MDG1's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Age and Tenure
2.5yrs
Average Tenure
61yo
Average Age
Experienced Board: MDG1's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.
Management Team
Horst Domdey (68yo)
Co-Founder & Member of the Supervisory Board
- Tenure: 7yrs
- Compensation: €43.00k
Ernst-Ludwig Winnacker (78yo)
Co-Founder & Chairman Scientific Advisory Board
- Tenure: 2.4yrs
- Compensation: €20.00k
Kai Pinkernell
Chief Medical Officer
- Tenure: 1.8yrs
- Compensation: €513.93k
Gary Waanders
Vice President of Investor Relations
- Tenure: 0.3yrs
Dolores Schendel
CEO, Chief Scientific Officer & Member of Executive Management Board
- Tenure: 3.9yrs
- Compensation: €568.00k
Axel-Sven Malkomes
CFO, Chief Business Development Officer & Member of Executive Management Board
- Tenure: 0.8yrs
Board Members
Keith Manchester (51yo)
Member of Supervisory Board
- Tenure: 2.7yrs
- Compensation: €23.00k
Horst Domdey (68yo)
Co-Founder & Member of the Supervisory Board
- Tenure: 7yrs
- Compensation: €43.00k
Ernst-Ludwig Winnacker (78yo)
Co-Founder & Chairman Scientific Advisory Board
- Tenure: 2.4yrs
- Compensation: €20.00k
Antoinette Hiebeler-Hasner (61yo)
Deputy Chairwomen of the Supervisory Board
- Tenure: 3.4yrs
- Compensation: €35.00k
Gerd Zettlmeissl (64yo)
Chairman of the Supervisory Board
- Tenure: 0.7yrs
- Compensation: €26.00k
Ron Scott (64yo)
Member of Supervisory Board
- Tenure: 2.7yrs
- Compensation: €27.00k
Frank Mathias (57yo)
Member of the Supervisory Board
- Tenure: 1.7yrs
- Compensation: €18.00k
Peter Krammer (53yo)
Member of Scientific Advisory Board
- Tenure: 2.4yrs
Yi-Ta Lee (48yo)
Member of the Supervisory Board
- Tenure: 6.5yrs
- Compensation: €25.00k
Micha Drukker
Member of Scientific Advisory Board
- Tenure: 2.4yrs
Company Information
Medigene AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Medigene AG
- Ticker: MDG1
- Exchange: XTRA
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €149.341m
- Shares outstanding: 24.56m
- Website: https://www.medigene.com
Number of Employees
Location
- Medigene AG
- Lochhamer Strasse 11
- Planegg/Martinsried
- Munich
- Bavaria
- 82152
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MDG1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2000 |
| MDG1 | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jun 2000 |
| 0QGJ | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Jun 2000 |
| MDGE.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Jun 2000 |
| MDG1D | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | EUR | Jun 2000 |
| MDG1 | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jun 2000 |
| MDG1 | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jun 2000 |
| MDG1 | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jun 2000 |
Biography
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/22 21:25 |
| End of Day Share Price | 2020/01/22 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.